Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
skin and connective tissue diseases | D017437 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
breast neoplasms | EFO_0003869 | D001943 | C50 |
male breast neoplasms | — | D018567 | — |
Expiration | Code | ||
---|---|---|---|
ALPELISIB, VIJOICE, NOVARTIS | |||
2029-04-05 | ODE-396 | ||
2024-05-24 | NCE | ||
ALPELISIB, PIQRAY, NOVARTIS | |||
2024-05-24 | NCE |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 20 | 23 | 7 | 1 | 9 | 55 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Triple negative breast neoplasms | D064726 | — | — | 3 | 5 | 1 | — | — | 9 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | — | 1 | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 9 | 5 | — | — | 1 | 13 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | 4 | 5 | — | — | 1 | 8 |
Squamous cell carcinoma | D002294 | — | — | 1 | 2 | — | — | — | 2 |
Colorectal neoplasms | D015179 | — | — | 1 | 2 | — | — | — | 2 |
Head and neck neoplasms | D006258 | — | — | 1 | 1 | — | — | — | 2 |
Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | 1 | — | — | — | 2 |
Lymphangioma | D008202 | — | D18.1 | — | 1 | — | — | 1 | 2 |
Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
Gastrointestinal neoplasms | D005770 | — | C26.9 | — | 1 | — | — | — | 1 |
Oropharyngeal neoplasms | D009959 | — | — | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hyperinsulinism | D006946 | HP_0000842 | E16.1 | 2 | — | — | — | — | 2 |
Rectal neoplasms | D012004 | — | — | 1 | — | — | — | — | 1 |
Esophageal squamous cell carcinoma | D000077277 | — | — | 1 | — | — | — | — | 1 |
Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | — | — | — | — | 1 |
Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | 1 | — | — | — | — | 1 |
Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
Esophageal neoplasms | D004938 | — | C15 | 1 | — | — | — | — | 1 |
Meningioma | D008579 | EFO_0003098 | D32.9 | 1 | — | — | — | — | 1 |
Drug common name | Alpelisib |
INN | alpelisib |
Description | (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide is a proline derivative. |
Classification | Small molecule |
Drug class | phosphatidylinositol 3-kinase (PI3K) inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1 |
PDB | — |
CAS-ID | 1217486-47-9 |
RxCUI | — |
ChEMBL ID | CHEMBL2396661 |
ChEBI ID | — |
PubChem CID | 56649450 |
DrugBank | DB12015 |
UNII ID | 08W5N2C97Q (ChemIDplus, GSRS) |